We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ACA:EURONEXT PARISCredit Agricole SA Analysis

Data as of 2026-07-10 - not real-time

$144.97

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Arcosa trades at $144.97, comfortably above its 20‑day (≈$139.65) and 50‑day (≈$130.74) moving averages, confirming a bullish price trend, yet the RSI sits at roughly 69.5, signaling near‑overbought conditions, and the MACD histogram has turned negative, giving a bearish signal despite the overall bullish direction. Volatility is elevated at about 29% over the past 30 days and beta exceeds 1, while the Fear & Greed Index reads “Extreme Greed,” suggesting strong market enthusiasm but heightened risk.
Fundamentally, the company posted 4.4% revenue growth with thin operating (≈8.6%) and profit margins (≈7.7%), carries a sizable debt load ($1.58 B) versus modest cash ($153 M), and trades at a P/E of ~32.6 versus an industry average of ~31.1, indicating a slight premium. The recent $450 M divestiture of its barge business sharpens focus on higher‑margin construction and engineered structures and has prompted an upward revision of full‑year guidance, though an activist investigation into the deal price adds a corporate‑governance risk. The dividend yield is low (0.14%) but the payout ratio is under 5%, making the payout sustainable.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near 52‑week high with overbought RSI
  • Bearish MACD crossover
  • Elevated short‑term volatility

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Raised revenue and EBITDA guidance after barge divestiture
  • Shift toward higher‑margin infrastructure segments
  • Upside potential of roughly 36% versus current price

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Strategic focus on construction and engineered structures with durable demand
  • Sustainable dividend despite low yield
  • Improving leverage as cash flow from core segments grows

Key Metrics & Analysis

Financial Health

Revenue Growth4.40%
Profit Margin7.66%
P/E Ratio32.6
ROE8.62%
ROA4.00%
Debt/Equity59.55
P/B Ratio2.7
Op. Cash Flow$413.7M
Free Cash Flow$55.3M
Industry P/E31.1

Technical Analysis

TrendBullish
RSI69.5
Support$122.40
Resistance$146.92
MA 20$139.65
MA 50$130.74
MA 200$113.11
MACDBearish
VolumeStable
Fear & Greed Index92.77

Valuation

Target Price$145.50
Upside/Downside0.37%
GradeFair
TypeBlend
Dividend Yield0.14%

Risk Assessment

Beta1.29
Volatility29.08%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.